OOIR: Observatory of International Research

Papers

(The TQCC of Molecular Neurodegeneration is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson’s disease	258
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies	211
Microbiota in neuroinflammation and synaptic dysfunction: a focus on Alzheimer’s disease	145
Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration	143
Neuropathology and molecular diagnosis of Synucleinopathies	142
Tauopathies: new perspectives and challenges	142
APOE2: protective mechanism and therapeutic implications for Alzheimer’s disease	135
TDP-43 Pathology in Alzheimer’s Disease	132
Proteomic landscape of Alzheimer’s Disease: novel insights into pathogenesis and biomarker discovery	126
“Don’t Phos Over Tau”: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer’s disease and other tauopathies	126
Solving neurodegeneration: common mechanisms and strategies for new treatments	122
Comprehensive metabolic profiling of Parkinson’s disease by liquid chromatography-mass spectrometry	121
Plaque associated microglia hyper-secrete extracellular vesicles and accelerate tau propagation in a humanized APP mouse model	120
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics	119
Extracellular protein components of amyloid plaques and their roles in Alzheimer’s disease pathology	115
METTL3-dependent RNA m6A dysregulation contributes to neurodegeneration in Alzheimer’s disease through aberrant cell cycle events	114
A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis	113
Cellular and pathological heterogeneity of primary tauopathies	112
Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination	106
New approaches to symptomatic treatments for Alzheimer’s disease	104
Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer’s disease: a systematic review of symptom-general and –specific lesion patterns	101
Post-infection cognitive impairments in a cohort of elderly patients with COVID-19	100
APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer’s disease pathology and brain diseases	99
Plaque-associated human microglia accumulate lipid droplets in a chimeric model of Alzheimer’s disease	95
Microbial-derived metabolites as a risk factor of age-related cognitive decline and dementia	90

The gut microbiome in Alzheimer’s disease: what we know and what remains to be explored	82
Protective genes and pathways in Alzheimer’s disease: moving towards precision interventions	72
The role of inflammasomes in vascular cognitive impairment	70
The promise of microRNA-based therapies in Alzheimer’s disease: challenges and perspectives	70
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications	69
Constitutively active SARM1 variants that induce neuropathy are enriched in ALS patients	68
Characterization of mitochondrial DNA quantity and quality in the human aged and Alzheimer’s disease brain	67
Genome-wide histone acetylation analysis reveals altered transcriptional regulation in the Parkinson’s disease brain	62
Pathophysiology and probable etiology of cerebral small vessel disease in vascular dementia and Alzheimer’s disease	61
Adult-onset CNS myelin sulfatide deficiency is sufficient to cause Alzheimer’s disease-like neuroinflammation and cognitive impairment	61
The landscape of human tissue and cell type specific expression and co-regulation of senescence genes	60
Clusterin secreted from astrocyte promotes excitatory synaptic transmission and ameliorates Alzheimer’s disease neuropathology	59
Microglial TYROBP/DAP12 in Alzheimer’s disease: Transduction of physiological and pathological signals across TREM2	58
TREM2 in the pathogenesis of AD: a lipid metabolism regulator and potential metabolic therapeutic target	57
Guidelines for bioinformatics of single-cell sequencing data analysis in Alzheimer’s disease: review, recommendation, implementation and application	57
TREM2 dependent and independent functions of microglia in Alzheimer’s disease	56
Trem2 deletion enhances tau dispersion and pathology through microglia exosomes	55
The informed road map to prevention of Alzheimer Disease: A call to arms	55
Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis	55
The CD33 short isoform is a gain-of-function variant that enhances Aβ1–42 phagocytosis in microglia	53
Identification of sixteen novel candidate genes for late onset Parkinson’s disease	52
Cholesterol alters mitophagy by impairing optineurin recruitment and lysosomal clearance in Alzheimer’s disease	48
Alzheimer’s disease – the journey of a healthy brain into organ failure	48
Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia	48
Sleep and circadian rhythms in Parkinson’s disease and preclinical models	47
CX3CR1 deficiency aggravates amyloid driven neuronal pathology and cognitive decline in Alzheimer’s disease	47
APOΕ4 lowers energy expenditure in females and impairs glucose oxidation by increasing flux through aerobic glycolysis	45
A novel systems biology approach to evaluate mouse models of late-onset Alzheimer’s disease	45
BIN1 is a key regulator of proinflammatory and neurodegeneration-related activation in microglia	44
Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain	43
Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis	42
Mitochondrial dysfunction in Parkinson’s disease – a key disease hallmark with therapeutic potential	42
Enhancing GABAergic signaling ameliorates aberrant gamma oscillations of olfactory bulb in AD mouse models	41
Adiponectin-mimetic novel nonapeptide rescues aberrant neuronal metabolic-associated memory deficits in Alzheimer’s disease	40
LRP1 is a neuronal receptor for α-synuclein uptake and spread	40
Extrasynaptic NMDA receptors in acute and chronic excitotoxicity: implications for preventive treatments of ischemic stroke and late-onset Alzheimer’s disease	39
Mitochondrial complex I abnormalities is associated with tau and clinical symptoms in mild Alzheimer’s disease	39
Knock-in models related to Alzheimer’s disease: synaptic transmission, plaques and the role of microglia	39
Human iPSC-derived astrocytes transplanted into the mouse brain undergo morphological changes in response to amyloid-β plaques	37
Anti-amyloid therapies for Alzheimer disease: finally, good news for patients	36
Culture shock: microglial heterogeneity, activation, and disrupted single-cell microglial networks in vitro	36
Tau interactome and RNA binding proteins in neurodegenerative diseases	36
Accumulation of saposin in dystrophic neurites is linked to impaired lysosomal functions in Alzheimer’s disease brains	36
Basal lamina changes in neurodegenerative disorders	35
Tauopathy-associated tau modifications selectively impact neurodegeneration and mitophagy in a novel C. elegans single-copy transgenic model	35
The era of cryptic exons: implications for ALS-FTD	35
Altered network properties in C9ORF72 repeat expansion cortical neurons are due to synaptic dysfunction	35
Preclinical modeling of chronic inhibition of the Parkinson’s disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo	34
Discrimination of MSA-P and MSA-C by RT-QuIC analysis of olfactory mucosa: the first assessment of assay reproducibility between two specialized laboratories	34
AMPK hyperactivation promotes dendrite retraction, synaptic loss, and neuronal dysfunction in glaucoma	34

The role of inflammation in neurodegeneration: novel insights into the role of the immune system in C9orf72 HRE-mediated ALS/FTD	33
Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease	33
TREM2/PLCγ2 signalling in immune cells: function, structural insight, and potential therapeutic modulation	33
Dynamic changes of CSF sPDGFRβ during ageing and AD progression and associations with CSF ATN biomarkers	32
Induction of autophagy mitigates TDP-43 pathology and translational repression of neurofilament mRNAs in mouse models of ALS/FTD	32
Parkinson mice show functional and molecular changes in the gut long before motoric disease onset	32
Astrocyte-derived clusterin suppresses amyloid formation in vivo	31
Impaired antioxidant KEAP1-NRF2 system in amyotrophic lateral sclerosis: NRF2 activation as a potential therapeutic strategy	31
Cellular stress signaling and the unfolded protein response in retinal degeneration: mechanisms and therapeutic implications	30
Neuropathology of incidental Lewy body & prodromal Parkinson’s disease	30
The role of peripheral inflammatory insults in Alzheimer’s disease: a review and research roadmap	30
Challenge accepted: uncovering the role of rare genetic variants in Alzheimer’s disease	29
Nuclear speckle specific hnRNP D-like prevents age- and AD-related cognitive decline by modulating RNA splicing	29
FUS-ALS hiPSC-derived astrocytes impair human motor units through both gain-of-toxicity and loss-of-support mechanisms	29
Opposing effects of apoE2 and apoE4 on microglial activation and lipid metabolism in response to demyelination	29